- Investing Ideas
- /
- Australian Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Australian Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
4
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
4 companies
Telix Pharmaceuticals
Market Cap: AU$4.8b
A commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals.
TLX
AU$14.20
7D
-7.3%
1Y
-37.7%
Immutep
Market Cap: AU$404.8m
A biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia.
IMM
AU$0.28
7D
9.8%
1Y
-11.1%
Cynata Therapeutics
Market Cap: AU$58.2m
Engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.
CYP
AU$0.26
7D
13.0%
1Y
15.6%
Aroa Biosurgery
Market Cap: AU$248.4m
Develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally.
ARX
AU$0.69
7D
-12.2%
1Y
8.7%